Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
06 janv. 2025 03h53 HE
|
Oculis Holding AG
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential...
Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða
06 janv. 2025 03h47 HE
|
Oculis Holding AG
ZUG, Sviss, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 var öruggt og þoldist vel í samanburði við lyfleysu.Tölfræðilega marktækar framfarir á virkni samanborið við lyfleysu, m.a. fyrir þykkt sjónhimnu...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
06 janv. 2025 03h47 HE
|
Oculis Holding AG
ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary efficacy...
Oculis Publishes Notification of Major Changes in Voting Rights
03 janv. 2025 18h48 HE
|
Oculis Holding AG
ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights, in relation to Brunnur vaxtarsjóður slhf‘s distribution of its shares in Oculis...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
06 déc. 2024 16h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Attachments
...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
29 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities
27 nov. 2024 04h15 HE
|
Oculis Holding AG
ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the...
Oculis to Present at the Stifel 2024 Healthcare Conference
13 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis to Present at the Stifel 2024 Healthcare Conference
13 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today...
Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
07 nov. 2024 04h00 HE
|
Oculis Holding AG
ZUG, Sviss, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Veruleg framvinda þróunarlyfja, þar á meðal innritun í OCS-01 DIAMOND fasa 3 rannsókninni á sjónhimnubjúg í sykursýki (DME) og OCS-05 fasa 2 ACUITY...